Dr. Ghosh on the Impact of Ide-Cel in Relapsed/Refractory Multiple Myeloma

Monalisa Ghosh, MD, a clinical assistant professor at the University of Michigan, discusses the impact of idecabtagene vicleucel (Abecma) in patients with relapsed/refractory multiple myeloma.

The agent was FDA approved in March 2021, based on the pivotal phase 2 KarMMA trial (NCT03361748), which studied the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma. The KarMMA trial featured an efficacy-evaluable population of 100 patients, according to Ghosh. Moreover, patients had received 4 or more prior lines of therapy. 

The trial was important, as it took a population of patients without many treatment options and provided a new promising prospect for therapy, Ghosh concludes.